Actelion Gets Early Benefits From Savings Plan, Awaits Opsumit Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
With a cost-saving initiative boosting earnings now rather than in 2014 there may be even greater pressure on Actelion’s next-generation PAH therapy – which has a PDUFA date of Oct. 19 – to replace the Swiss company’s aging top-selling product, Tracleer.